Inventiva S.A. Form 6-K Summary
Business context and reporting period
Inventiva S.A. filed this Form 6-K on September 27, 2022, for September 2022. The filing reports a material definitive agreement, dated September 21, 2022, with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. for the development and commercialization of lanifibranor in Mainland China, Hong Kong, Macau, and Taiwan.
Key financial and operating terms
- Upfront payment: $12 million payable upon signing.
- Development and regulatory milestones: Up to $40 million in aggregate.
- Commercial milestones: Up to $250 million in aggregate.
- Royalties: Tiered royalties ranging from high single-digit to mid-teen double-digit percentages of net sales during the first three years after first sale, and low- to mid-teen double-digit percentages thereafter, subject to regulatory approval and other agreement terms.
- Costs and responsibilities: The licensee will fund trials and regulatory activities in the territory and bear commercialization costs. The licensee may either join Inventiva’s ongoing NATiV3 Phase III trial or conduct an independent trial, subject to Chinese regulatory approval.
- Current financial metrics: This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or balance-sheet figures. It also does not state whether the upfront payment had been received by the filing date.
Material changes versus the prior comparable period
The filing does not present comparative financial statements or period-over-period operating results. The material change disclosed is the execution of the exclusive Greater China licensing and collaboration agreement for lanifibranor.
Guidance, outlook, risks, and unusual items
- The agreement could provide access to development funding, milestone payments, commercial milestone payments, and future royalties, but receipt and timing depend on clinical, regulatory, and commercial achievements.
- Lanifibranor is being evaluated in the NATiV3 Phase III clinical trial for adults with NASH. The licensee’s participation in NATiV3 or an independent study depends on regulatory and other factors.
- Inventiva remains a clinical-stage company with no approved products, no historical product-sales revenue, significant accumulated losses, and a stated need for additional capital to finance operations.
- Key risks include clinical-trial delays or failures, inability to demonstrate safety or efficacy, adverse drug reactions, patient recruitment and retention challenges, regulatory nonapproval, commercialization difficulties, competition, and failure to achieve milestones or royalties.
- The filing also identifies potential effects from COVID-19, geopolitical events including the Russia-Ukraine conflict, sanctions, inflation, macroeconomic conditions, and financial-market volatility.
- Certain confidential provisions of the attached licensing agreement were omitted.
Important facts for investors to verify
- Whether and when the $12 million upfront payment was received and recognized under applicable accounting rules.
- The specific development, regulatory, and commercial milestone conditions, payment timing, and any omitted confidential provisions.
- The regulatory pathway and decision regarding participation in NATiV3 versus an independent Greater China trial.
- Inventiva’s cash balance, cash runway, capital needs, debt, and operating results in the June 30, 2022 half-year report.
- Whether clinical, regulatory, manufacturing, or commercialization events could delay or prevent milestone and royalty payments.